Background: Protease serine 8 (PRSS8), a trypsin-like serine peptidase, has been shown to function as a tumour suppressor in various malignancies. The present study aimed to investigate the expression pattern, prognostic value and the biological role of PRSS8 in human hepatocellular carcinoma (HCC). Methods: PRSS8 expression in 106 HCC surgical specimens was examined by Real-time polymerase chain reaction (PCR) and immunohistochemistry, and its clinical significance was analysed. The role of PRSS8 in cell proliferation, apoptosis and invasion were examined in vitro and in vivo. Results: PRSS8 mRNA and protein expression were decreased in most HCC tumours from that in matched adjacent non-tumour tissues. Low intratumoral PRSS8 expression was significantly correlated with poor overall survival (OS) in patients with HCC (P = 0.001). PRSS8 expression was an independent prognostic factor for OS (hazard ratio [HR] = 1.704, P = 0.009). Furthermore, restoring PRSS8 expression in high metastatic HCCLM3 cells significantly inhibited cell proliferation and invasion. In contrast, silencing PRSS8 expression in non-metastatic HepG2 cells significantly enhanced cell growth and invasion. Moreover, our in vivo data revealed that attenuated PRSS8 expression in HepG2 cells greatly promoted tumour growth, while overexpression of PRSS8 remarkably inhibited tumour growth in an HCCLM3 xenograft model. Enhanced cell growth and invasion ability mediated by the loss of PRSS8 expression was associated with downregulation of PTEN, Bax and E-cadherin and an upregulation in Bcl-2, MMP9 and N-cadherin. Conclusions: Our data demonstrate that PRSS8 may serve as a tumour suppressor in HCC progression, and represent a valuable prognostic marker and potential therapeutic target for HCC.
Introduction
Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancerrelated deaths worldwide [1] . Surgical resection is one of the most reliable curative treatment modalities in selected patients. However, one of the major obstacles in improving outcomes following resection is the high frequency of recurrence and metastasis. Therefore, a more comprehensive understanding of the molecular mechanisms involved in HCC carcinogenesis and identification of genetic or epigenetic alterations will be critical for improving diagnosis, therapy and predicting the prognosis for this disease.
PRSS8 (protease serine 8), also known as Prostasin, is a glycosyl-phosphatidyl-inositol (GPI)-anchored extracellular serine protease which was first purified from seminal fluid in 1996 [2] . It is highly expressed in normal prostate epithelia and is found in prostate gland, kidney, bronchi, colon, liver, lung, pancreas, and salivary glands [3] . The protein is implicated in epithelial sodium channel regulation and essential for terminal epithelial differentiation [4, 5] . Recently, the loss of PRSS8 has been detected in a various human cancers, including prostate cancer [6] , breast cancer [7] , bladder cancer [8] , gastric cancer [9] , colorectal cancer [10] as well as esophageal squamous cell carcinomas [11] . Although several functions of PRSS8 are unknown, research has demonstrated that PRSS8 is a potential tumour suppressor gene [10] . However, the clinical significance and function of PRSS8 in HCC are unknown.
Here we analysed the expression status of PRSS8 in HCC tissues and cell lines using quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and immunohistochemistry. Moreover, we identified the correlations between PRSS8 expression and clinicopathological features and evaluated its prognostic value in patients with HCC. Furthermore, we investigated the functional role of PRSS8 in tumour growth, apoptosis and invasion using both in vitro and in vivo experiments.
Materials and Methods

Patients and tissue specimens
The study was approved by the ethics committee of Chinese PLA General Hospital (CHN-PLAGH-ZL-002), and informed consent was obtained from each patient according to the committee's regulations. A total of 106 paired tumour tissues and matched normal adjacent liver tissues were collected from patients with HCC that underwent resection at the Department of Gastroenterology and Hepatology at the Chinese PLA General Hospital between 2007 and 2010. The inclusion and exclusion criteria of the patients were: 1) having a distinctive pathologic diagnosis of HCC; 2) an absence of preoperative chemotherapy or radiotherapy, and extrahepatic metastases; 3) underwent a primary and curative liver resection; and 4) had complete clinicopathological information and follow-up data. TNM classification was used to determine the tumour stages according to the 2002 International Union Against Cancer guidelines. Tumour differentiation was graded according to the Edmondson-Steiner classification. Clinical characteristics of all patients are presented in Table 1 . Data were censored at the last follow-up for patients without recurrence or death. The time to overall survival (OS) time were defined as the interval from primary surgical treatment to death. All excised samples were obtained from tumour tissues within 1 h after surgery. For each specimen, half of the tissue was immediately immersed in RNAlater (Ambion, Inc., Austin, TX, USA) to avoid RNA degradation and was then frozen at −80°C until the RNA and protein extraction was performed. The remaining half was fixed in 10% formalin for immunohistochemistry.
Mice and cell lines
Male 6-8 week-old BALB/c nu/nu mice (Charles River Laboratories, Beijing, China) were housed under specific pathogen-free conditions. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985). The animal study was approved by the Research Ethics Committee of Chinese PLA General Hospital. Four human HCC cell lines, including HCCLM3 (high metastatic HCC cell line), Huh7, Hep3B and HepG2 (non-metastatic human HCC cell RNA extraction and qRT-CR Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA concentration was assessed by measuring the absorbance at 260 nm using a NanoDrop spectrophotometer (ND-1000, Thermo Scientific, Waltham, MA, USA). A 2-μg sample of the total RNA was reverse transcribed using M-MLV reverse transcriptase (Life Technologies Inc., Gaithersburg, MD, USA) according to the manufacturer's recommendations. The resulting cDNA was then subjected to qRT-PCR for evaluation of the relative mRNA levels of PRSS8 and β-actin using the following primers: PRSS8 forward: 5′-GTGCCTCTGATCAGTCGTGA -3′ reverse: 5′-TACCAGAGACCCTCCACAGG -3′ β-actin forward: 5′-GTGGACATCCGCAAAGAC-3′ reverse: 5′-AAAGGGTGTAACGCAACTA-3′ Gene-specific amplification was performed using the ABI 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) with the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The expression level of PRSS8 was normalised to that of the housekeeping gene β-actin using the comparative threshold cycle (2 −ΔCt ) method.
Immunohistochemistry and scoring
The tumour specimens were fixed in 10% neutral formalin, embedded in paraffin and 4-μm-thick sections were prepared. The immunohistochemistry streptavidin peroxidase conjugated method was used to detect the expression of PRSS8. Briefly, tissues were treated with 3% H 2 O 2 methanol at room temperature for 10 min, and then incubated in 5% goat antiserum for 15 min at 37°C. After rinsing with phosphatebuffered saline (PBS), the sections were incubated with anti-PRSS8 antibody (ab203879, 1:100; Abcam, Cambridge, MA, USA) at 4°C overnight. The sections were then incubated with an secondary antibody for 30 min followed by further incubation with the streptavidin-horseradish peroxidase complex. The sections were developed with diaminobenzidine tetrahydrochloride and then counterstained with haematoxylin.
The total PRSS8 immunostaining score was calculated as the sum of the percept of positively stained tumour cells and the staining intensity. Briefly, five fields were randomly selected, and three slides for each specimen were counted. The staining extent was scored from 0 to 3 based on the percentage of positive cells (0: <10%; 1: 10%-25%; 2: 25%-50% and 3: >50%). The intensity of the staining was scored as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining), respectively. The final PRSS8 expression score was calculated using the percentage of positive cells score × staining intensity, ranging between 0-9. Positive PRSS8 expression was defined as a total score of ≥1, and low PRSS8 expression as a total score of 0. For the negative control, the primary antibody was replaced with PBS. When there were discrepancies between the two pathologists in their scoring, an average score was used.
Construction of PRSS8 silencing and overexpressing cell lines PRSS8 gene expression was silenced in HepG2 cells and overexpressed in HCCLM3 cells. To knockdown PRSS8, the LV-GFP-PRSS8 lentiviral vector (i.e. HepG2-shRNA-PRSS8) and mock vector (i.e. HepG2-shRNA-Mock) were purchased from Shanghai GeneChem Co. (Shanghai, China). The interference RNA sequences were: PRSS8 shRNA-1:CCGGATCACCTTCTCCCGCTACATCCTCGAGGATGTAGCGGGAGAAGGTG ATTTTTTG; PRSS8 shRNA-2:CCGGGAGCACCACAAGGAAGCCTATCTCGAGATAGGCTTCCTTGTGGTGCTCTTTT TG. The lentiviral vectors were transfected into HepG2 cells according to the manufacturer's instructions. To overexpress PRSS8, full-length cDNA sequences for human PRSS8 cDNA were purchased from Sino Biological (Beijing, China). The full-length cDNA of PRSS8 was cloned into a pcDNA3.1 vector, and the recombinant plasmid pcDNA3.1-PRSS8 (i.e. HCCLM3-pcDNA3.1-PRSS8) and control plasmid (i.e. HCCLM3-pcDNA3.1-Mock) were transfected into HCCLM3 cells using Lipofectamine™2000 (Invitrogen, Carlsbad, CA, USA). After transfection, the cells were diluted at a ratio of 1:5 into a 12-well plate and the medium was replaced with a medium containing G418 (600 μg/mL). Two stable cell clones were obtained after 28 days by screening for G418. Stably transfected clones were validated by qRT-PCR and Western blotting to determine the level of target gene expression.
Western blotting
A 20-μg sample of the total protein from HCC cell lines and their derivatives was extracted and separated by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). After which, the protein was transferred onto a polyvinylidene fluoride membrane, and the membrane was incubated overnight at 4°C with a mouse monoclonal antibody against PRSS8 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes were then washed three times with Tris-buffered saline with tween-20 and probed with a horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG antibody (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 37°C for 1 h. The bands were then visualized using BioImaging Systems (UVP Inc., Upland, CA, USA). The protein levels were normalized to those of β-actin, detected using a mouse anti-human β-actin monoclonal antibody (1:1500, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Cell proliferation assay
Cellular proliferation was evaluated using Cell Counting Kit-8 (CCK-8; Beyotime Biotechnology, Haimen, China) according to the manufacturer's instructions. Briefly, cells were seeded into 96-well plates at a density of 5 × 10 3 cells per well and cultured for the indicated time periods. Optical density values were read using a microplate reader (Bio-Tek Company, Winooski, VT, USA) at a wavelength of 450 nm. Each time point was performed in triplicate, and the experiment was performed three independent times.
Cell cycle assay
The cell cycle was evaluated using the Click-it ® EdU Alexa Fluor ® Flow Cytometry Assay Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, cells were seeded into 6-well plates at a density of 1 × 10 6 cells per well, and synchronised for 24 h in serum-free medium. Cellular proliferation was re-initiated with the addition of a serum-containing medium for 1 h in the presence of EdU (5-ethynyl-2′-deoxyuridine; 10 µM). The cells were then fixed and incubated with the cell cycle dye, 7-aminoactinomycin D (7-AAD), for 30 min just prior to running flow cytometry (BD FACSCalibur, BD Bioscience, San Diego, CA, USA). Data acquisition and analysis were performed using FlowJo software (FlowJo, Ashland, OR, USA).
Cell apoptosis assay
Cell apoptosis was evaluated by flow cytometry using an Annexin V-FITC Apoptosis Detection Kit (KeyGen Biotech Co., Nanjing, China). Briefly, cells were detached from the culture well by trypsinisation, washed twice with PBS, and resuspended in 500-μL binding buffer. A volume of 5-μL Annexin V-FITC and 5-μL propidium iodide was added and the solution was mixed gently. The cells were then stained in the dark for 10 min at room temperature and analysed immediately by flow cytometry (BD FACSCalibur, BD Bioscience, San Diego, CA, USA). The data was analysed using FlowJo software (FlowJo, Ashland, OR, USA) and the experiment was repeated three times.
Cell invasion assay
Cell invasion assays were performed using 24-well transwells (8-μm pore size; Minipore, Billerica, MA, USA) pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, 2 × 10 5 cells were suspended in 200-μL DMEM medium supplemented with 1% FBS and the cell solution was then added to the upper chamber. A volume of 600 μL of DMEM containing 10% FBS was placed in the lower chamber. After incubating for 48 h, the Matrigel and the cells remaining in the upper chamber were removed using cotton swabs. Cells on the lower surface of the membrane were fixed with 4% paraformaldehyde and stained with Giemsa (Sigma-Aldrich, St. Louis, MO, USA). Five microscopic fields (at 200× magnification) were used to count and photograph the cells.
In vivo tumour growth assay
A sample of 1 × 10 6 HCCLM3 cells were stably transfected with either PRSS8 (i.e. HCCLM3-pcDNA3.1-PRSS8) or the control plasmid expression vector (i.e. HCCLM3-pcDNA3.1-Mock) and injected subcutaneously into the flank region of 6-8-week-old male nude mice (n = 10 per group). A sample of 2 × 10 6 HepG2 cells stably transfected with either PRSS8 shRNA (i.e. HepG2-shRNA-PRSS8) or the control shRNA (i.e. HepG2-shRNA-Mock) were subcutaneously injected into the flank region of 6-8-week-old male nude mice (n = 10 per group). Tumour growth was monitored every 5 days for 5 weeks, and the tumours were measured with fine digital callipers. The tumour volume was calculated using the following formula:
tumour volume = 0.5 × width 2 × length
Statistical analysis
Statistical analyses were carried out using the Statistical Package for the Social Sciences 16.0 for Windows (SPSS, Chicago, IL, USA). Differences in mRNA and protein expression were evaluated using a paired-samples t-test. The relationship between PRSS8 expression and various clinicopathological parameters were analysed by a chi-square test. Survival curves were plotted using the KaplanMeier method and compared using the log-rank test. The Cox proportional hazard regression model was used for univariate and multivariate analyses (forward stepwise selection [Wald] method; P < 0.05 was selected for entry into the model, and P > 0.05 was selected for removal) to study the effects of the clinicopathological variables and PRSS8 expression on survival. Other results were assessed using a two-tailed unpaired Student's t-test. P < 0.05 was considered to be statistically significant.
Results
PRSS8 expression is downregulated in HCC tissues
We first determined PRSS8 mRNA expression in 106 paired tumour and matched adjacent normal liver tissues by qRT-PCR. As shown in Figure 1a , the expression level of PRSS8 was significantly lower in the tumour tissues than in the adjacent tumourfree tissues (0.031 ± 0.002 vs. 0.052 ± 0.003, P < 0.001). We subsequently performed immunohistochemical analyses of the 106 paraffinembedded paired HCC tissue blocks to detect the level of PRSS8 protein expression. Typical immunostaining of PRSS8 expression in tumours or non-tumours are presented in Figure  1b . The expression of PRSS8 was significantly higher in the normal liver tissues than in the HCC tissues (χ 2 = 13.787, P < 0.001). Specifically, 54 of 106 (50.9%) cases exhibited high PRSS8 immunostaining in the tumour tissues, whereas 81 of 106 (76.4%) cases showed high PRSS8 staining in the adjacent normal liver tissues (Fig. 1c) . We further confirmed the lower PRSS8 expression by western blot analysis of whole liver tissue extracts (Fig. 1d) . These results suggest that PRSS8 expression is downregulated in HCC. 
Low PRSS8 expression is correlated with a poor prognosis of HCC
The relationships between the intratumoral PRSS8 expression and various clinicopathological characteristics are listed in Table 1 . The data indicates that the low PRSS8 expression was significantly correlated with age (P = 0.01), ALT level (P = 0.034), vascular invasion (P = 0.006), tumour differentiation (P = 0.009) and TNM stage (P = 0.023), but not with gender, hepatitis history, liver cirrhosis history, AFP level, GGT level, tumour size or tumour multiplicity.
The 5-year OS rates in patients with high and low PRSS8 expression was 48.9% and 24.9%, respectively. The overall survival of patients with a high intratumoral PRSS8 level was significantly longer than the survival of those with reduced PRSS8 levels (P = 0.001; Fig. 1e ). The univariate analyses found that liver cirrhosis, AFP level, GGT level, tumour size, vascular invasion tumour differentiation, TNM stage and PRSS8 expression were significantly associated with OS (Table 2) . Furthermore, the multivariate Cox regression analysis confirmed that the tumour size, vascular invasion tumour differentiation, TNM stage and PRSS8 expression were independent prognostic factors for OS in patients with HCC (Table 2) .
PRSS8 knockdown promotes HCC cell growth and invasion, whereas overexpression of PRSS8 inhibits HCC cell growth and invasion
In order to investigate the func- Table 2 . Univariate and multivariate analyses of factors associated with survival and recurrence of HCC patients. Abbreviations: OS, overall survival; TTR, time to recurrence; N.A., not adopted; AFP, alpha-fetoprotein; ALT, Alanine transaminase; GGT, γ-glutamyl transferase; TNM, tumor-node-metastasis; PRSS8, Protease serine 8 tion of PRSS8 in vitro and in vivo, we examined the expression of PRSS8 in multiple HCC cell lines (HCCLM3, Huh7, Hep3B, and HepG2) with different metastasis potential and in normal liver cell line (L02). The qRT-PCR and western blot data revealed that the expression of PRSS8 was lower in HCCLM3 cells and higher in both the HepG2 and L02 cells (Fig. 1f) . This suggests that there is a negative correlation between metastatic potential and PRSS8 expression. Based on the results mentioned above, we hypothesised that PRSS8 was implicated in HCC growth and metastasis. To analyse the function of PRSS8 in HCC, we silenced PRSS8 in HepG2 cells using lentivirus-delivered shRNA. Furthermore, we overexpressed PRSS8 in HCCLM3 cells using the pcDNA3.1 plasmid. As shown in Fig. 1g and h, the qRT-PCR and western blot data showed that the PRSS8 protein levels were significantly overexpressed in HCCLM3 transfected cells and significantly reduced in HepG2 cells from that in the mock control cells.
Using these stably transfected cell lines, we next evaluated the role of PRSS8 on cellular proliferation, cell cycle distribution, cell apoptosis and invasion. As shown in Fig. 2a , the time course CCK-8 assay revealed that 48 h after the cells were seeded, the cell viability of the HepG2 cells in the PRSS8 knockdown group was significantly higher than that of the mock controls (Fig. 2a) . In contrast, the cell viability in the PRSS8 over-expressed HCCLM3 cells was significantly lower than that in the pcDNA3.1 controls (Fig. 3a) . However, the cell cycle assay using EdU incorporation demonstrated that PRSS8 downregulation or overexpression did not affect the cell cycle distribution because no differences were observed between these distributions and that of the mock controls (Fig. 2b-c and 3b-c) . This indicates that PRSS8 inhibited tumour growth via inducing apoptosis. To confirm this hypothesis, a cell apoptosis assay was performed. As shown in Fig. 2d and e, the Annexin V/PI assay revealed that the percentage of apoptotic cells in the PRSS8 knockdown group of HepG2 cells was significantly lower than that in the mock control cells (Fig. 2d and e) . Furthermore, the percentage of apoptotic cells in the PRSS8 overexpressed group of HCCLM3 cells was significantly higher than that in the pcDNA3.1 control cells (Fig. 3d and e) . Additionally, an in vitro invasion assay showed that downregulation of PRSS8 in non-metastatic HepG2 cells promoted greater invasion ability than that of the cells transfected with the mock vectors ( Fig. 2f and g ), while the upregulation of PRSS8 in highly metastatic HCCLM3 cells led to decreased cell invasion ability in vitro, relative to that of the cells transfected with the control plasmid ( Fig. 3f and  g ). To confirm the above results, we performed function experiments using another shRNA targeting different region of PRSS8 for knocking down (for all online suppl. material, see www. karger.com/doi/10.1159/000453136, Fig. S1 ), and using another stable clone of HCCLM3 for overexpression experiments (Fig. S1) . We also further confirmed shRNA experiments using another HCC cell line Hep3B (Fig. S2) .
PRSS8 suppresses xenograft tumour growth in vivo
We next used a xenograft HCC model to elucidate the effects of PRSS8 on HCC progression in vivo. As shown in Fig. 4a and b, 5 weeks after tumour implantation, the tumour volume Fig. 3 . Overexpression of PRSS8 inhibits HCC cell growth and invasion. a. The cell viability influenced by PRSS8 was assessed by time course CCK-8 assay. b and c. The cell cycle distribution influenced by PRSS8 was assessed by EDU incorporation assay. d and e. The cell apoptosis influenced by PRSS8 was assessed by Annexin V/PI apoptosis detection assay. f and g. The cell invasion influenced by PRSS8 was assessed by Matrigel precoated Transwell assay. Data are shown as mean ± SD from three independent experiments.in PRSS8 knockdown xenografts was significantly larger than that of the xenografts derived from HepG2-controls (P < 0.05). Immunostaining showed that the endogenous PRSS8 was knocked-down by shRNA from xenografted tumors (see online suppl. material, Fig. S3 ). In addition, the tumour volume of the pcDNA3.1-PRSS8-derived xenografts was significantly smaller than that of the HCCLM3-mock-derived xenografts (P < 0.01).
PRSS8 affects tumour growth and metastasis through the modulation of Bcl2 and N-cadherin expression
To investigate the potential mechanism by which PRSS8 affects cellular proliferation and invasion, we explored the change in cell apoptosis and invasion-related molecules in these stably transfected cells. As shown in Fig. 4c , the downregulation of PRSS8 in HepG2 cells resulted in a significant reduction in PTEN, Bax and E-cadherin expression and striking increase in Bcl-2, MMP9 and N-cadherin expression. In addtion, the expression of PTEN, Bax and E-cadherin was significantly elevated, while the levels of Bcl-2, MMP9 and N-cadherin expression were markedly decreased in PRSS8 overexpressed HCCLM3 cells.
Discussion
Significant advances have been made in understanding hepatocarcinogenesis during recent decades. Despite these advances, the prognosis of HCC is still dismal and 5-year survival rate is less than 5% [12] . Therefore, a better knowledge of molecular mechanisms of hepatocarcinogenesis is crucial for HCC targeted therapy. PRSS8, a trypsin-like serine peptidase expressed in epithelial cells, has recently been classified as a novel tumour suppressor, as evidenced by aberrantly expression of PRSS8 in several cancers including prostate [6] , bladder [8] , gastric [9] , and colorectal cancers [10] . Restoration of PRSS8 in ovarian or colorectal cancer cells results in the inhibition of cell proliferation and invasion [10, 13] . However, the clinical significance of PRSS8 and its biological roles and associated mechanisms in HCC tumorigenesis remain unknown. Therefore, in the current study, we evaluated the comprehensive role of PRSS8 in human hepatocarcinogenesis.
Using qRT-PCR, western blot and tissue immunohistochemistry, we confirmed that: 1) PRSS8 exhibited reduced expression at both the mRNA and protein level in HCC tissues from that in the corresponding normal liver tissues; 2) PRSS8 expression was reduced in 52 out of 106 (49.1%) HCC tumour tissues, but only lost in 25 normal liver tissues; 3) the expression of PRSS8 was lower in the HCC cell lines than in the normal liver cell lines. In line with our results, Bao et al. reported that PRSS8 protein expression was decreased in 87 out of 282 (30.8%) tumour tissues from that in the adjacent non-tumorous counterparts in colorectal cancer [10] . In addition, Bao et al. also found reduced expression of PRSS8 in human ESCC [11] . However, the loss of PRSS8 protein expression occurred in 49.1% (52/106) of HCC tumours, with an even higher proportion (90%; 9/10) in high-grade (stage III) HCC, suggesting that the loss of PRSS8 is not uncommon in HCC. For instance, Chen reported that only 16.7% (2/12) of the cases were positive for PRSS8 staining in human high-grade (Grade III) bladder transitional cell carcinomas [8] . Taken together, our observations in the current study are in agreement with those in a series of previous studies revealing that PRSS8 expression is frequently lost or reduced in a number of cancerous tissues.
The current study also showed detailed correlations between the loss of PRSS8 expression, a variety of clinicopathological features and survival rate, which have not been previously studied. To date, there is coincidental surrounding the relevance of PRSS8 on survival. Several studies found that reduced PRSS8 expression were a predictor of worsened survival in gastric cancer [9] , colorectal cancer [10] and ESCC [11] . In our study, low PRSS8 expression was significantly correlated with vascular invasion, poor tumour differentiation and advanced TNM stage as well as shorter survival time. Moreover, there was a negative correlation between the metastatic potential and PRSS8 expression in the HCC cell lines, suggesting that loss of PRSS8 may be associated with metastasis of HCC. In addition, the survival analyses indicated that the reduced PRSS8 expression was an independent prognostic factor for poor OS. Collectively, our observation that the loss of PRSS8 expression in HCC is associated with more malignant phenotypes and a worsened prognosis indicate that PRSS8 may function as a tumour suppressor in HCC carcinogenesis.
In addition, we further investigated the functional role of PRSS8 in HCC cell lines. We utilised a plasmid to upregulate PRSS8 expression in the HCCLM3 cell line with low endogenous PRSS8 levels, and we silenced PRSS8 in HepG2 and Hep3B cells with high levels of endogenous PRSS8. We found that restoring PRSS8 expression in HCCLM3 cells significantly promotes cell apoptosis and inhibits cell invasion in vitro, while silencing the expression of PRSS8 in HepG2 and Hep3B cells reduced cellular apoptosis and enhanced cell invasion. Consistent with our findings, previous studies have suggested a role for PRSS8 in three processes relevant to tumour suppression: 1) proliferation, 2) apoptosis and 3) epithelial-mesenchymal transition (EMT). For both colorectal and ovarian cancer cell lines, the knockdown of PRSS8 enhanced cellular proliferation, whereas the overexpression of PRSS8 dampened the proliferation and induced cell apoptosis [10, 13] . Moreover, Chen et al., reported that loss of PRSS8 expression in the bladder cell carcinoma cell lines correlated with reduced E-cadherin expression [8] . Bao et al., found that restored PRSS8 expression in ESCC cells led to inhibition of cell migration [11] . These data, together with our findings, indicate that PRSS8 may play an import role in inhibiting tumour cell growth and metastasis.
The molecular mechanisms by which PRSS8 inhibits cancer cell proliferation and metastasis remain unclear. Bao et al. reported that the tumour suppressor role of PRSS8 was primarily involved in the negative regulation of Sphk1/S1P/Stat3 signalling pathways, which related to numerous cellular processes important for cell growth, survival and invasion [10] . In ovarian cancer, PRSS8 may suppress cancer cells by modulating the CASP/P21-activated protein kinase (PAK2)-p34 pathway, and thereafter PAK2-p34/JNK/c-jun and PAK2-p34/ mlck/actin signaling pathways [13] . In the present study, we examined the expression of the tumour suppressor protein PTEN, the cell apoptosis-related protein Bcl-2, Bax and the epithelial mesenchymal transition (EMT)-related protein E-cadherin, N-cadherin and MMP9.
We found that PRSS8 overexpression could increase PTEN protein levels, decrease Bcl-2 protein expression and increase Bax expression. The ratio of Bcl-2 protein (an inhibitor of apoptosis) to Bax protein (an inducer of apoptosis) determines survival or death in response to an apoptotic stimulus [14, 15] . Our results indicate that PRSS8 inhibits HCC cell growth via the activation of the intrinsic apoptotic pathway. Accumulating evidence shows that EMT is involved in tumour metastasis. EMT is associated with the progressive redistribution or downregulation of apical and basolateral epithelial cell-specific tight junctions (e.g. E-cadherin and cytokeratin), and the novel expression of mesenchymal molecules (e.g. N-cadherin) [16] . Here we found that restoring PRSS8 expression significantly reduced N-cadherin levels, but increased E-cadherin levels from those in the mock controls. In agreement with our results, Chen et al. found that re-expression of PRSS8 up-regulated E-cadherin expression in human transitional cell carcinomas KU-7 cells [8] . Another protein, MMP9, can degrade extracellular matrix components and thus, promote the invasion of tumour cells [17, 18] , and was also reduced in parallel with the upregulation of PRSS8. This suggests that PRSS8 may inhibit the metastasis and invasion of HCC through a switch from N-cadherin to E-cadherin expression, and the downregulation of MMP9.
In conclusion, our study has demonstrated for the first time that PRSS8 expression was reduced in HCC and its down-regulation was correlated with vascular invasion, advanced TNM stage, and a poor OS of patients with HCC. In addition, we verified that PRSS8 can inhibit tumour growth and invasion both in vitro and in vivo, possibly through modulating Bcl-2 and N-cadherin expression. Given these findings, our data demonstrate that PRSS8 may serve as a tumour suppressor in HCC progression, and represent a valuable prognostic marker and potential therapeutic target for HCC. Future studies are required to elucidate the specific molecular mechanisms by which PRSS8 functions as a tumour suppressor.
